Abstract
Twenty-two asymptomatic women with rising CA 125 levels after chemotherapy for ovarian cancer were entered into a trial of isotretinoin combined with calcitriol. Tumours were evaluated according to precise criteria based on serial CA 125 levels and by comparing regression slopes of CA 125 before and during therapy. There was no evidence based on CA 125 of any responses or significant change in tumour growth rate.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rustin, G., Quinnell, T., Johnson, J. et al. Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer. Br J Cancer 74, 1479–1481 (1996). https://doi.org/10.1038/bjc.1996.568
Issue Date:
DOI: https://doi.org/10.1038/bjc.1996.568
This article is cited by
-
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer
Cancer Chemotherapy and Pharmacology (2007)
-
Expression of VDR and CYP24A1 mRNA in human tumors
Cancer Chemotherapy and Pharmacology (2006)